MedTrace Logo

Comparison Between The Effects Of Different Frequencies Of Ultrasonic Cavitation On Abdominal Adiposity And Female Hormones In Polycystic Ovarian Syndrome

NCT05039125 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2021-09-09

No results posted yet for this study

Summary

Thirty women diagnosed with PCOS had participated in the study. They suffered from amenorrhea or oligo-menorrhea and subcapsular follicles. Their ages were from 20-35 years. Their BMI was from 30 - 35 kg/m². Their waist/hip ratio was ˃ 0.85. Their LH/FSH ratio was ≥ 1.5. They were recruited randomly from the outpatient clinic of gynecology in Minya governorate hospital. They were randomly assigned into two groups equal in number: (A and B); group A (n=15) received 40000HZ ultrasound cavitation, group B (n=15) received 2600HZ ultrasound cavitation. Treatment time was 30 minutes /sessions, 3 times/ week for two months. Both groups (A and B) received a low caloric diet (1200 Kcal/day). All participants had their medical treatment as prescribed by the physician.

Conditions

  • Polycystic Ovary Syndrome

Interventions

RADIATION

ultrasonic cavitation

* From a standing position, each participant's abdomen was divided transversally into three sections; resulting in a total of 6 abdominal segments. * Part III: 3cm above the umbilicus to 2cm below the umbilicus * After washing the skin on the anterior abdominal wall with alcohol, a conducting medium (gel) was placed to the ultrasonic instrument's cavitational head. * The gadget was turned on, a 30-minute timer was set, and the intensity was gradually increased. * The cavitation head then moved extremely gently in a small circular motion on each abdomen section for 5 minutes. * After completing the ultrasonic application to the six regions of the abdomen, the skin was cleansed with a piece of cotton. For group (A): 40000 HZ ultrasound was delivered for 30 minutes, 3 times/week for 2 months. For group (B):26000 HZ ultrasound was delivered for 30 minutes, 3 times/week for 2 months

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Principal Investigators

  • Ahmed Mohamed Maged M ElGoly · Cairo University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-30
Primary Completion
2021-01-11
Completion
2021-08-02

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05039125 on ClinicalTrials.gov